Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2299)	1/19/2006 5:39:46 PM
From: BulbaMan	Respond to of 7424

Thanks for the insight Rick. In my much, much less educated view, I agree there's certainly the potential the booster could have been directly responsible for the reduced efficacy. But there were so many potential confounding factors in the trial (e.g., the amounts of Sudafed and Allegra the trial groups self-administered could have differed) that the company may not even have a good theory about the booster by March. Nonetheless, overall, the trial results convince me Tolamba really does work.